BIOMERICA INC
Close on Oct 19, 2026
- Market cap
- $5.80M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2022 Ended Nov 30, 2021 | Dec 16, 2021 | Before market open | – | – | – |
Press releases
Announcements Biomerica filed with the SEC
NEWS - For Immediate Release
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Appoints Eric B. Chin to Board of Directors and Audit Committee Chair
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Expected to Begin Trading on Split-Adjusted Basis on April 21, 2025
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Public Offering of Common Stock
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Biomerica Announces Pricing of $8 Million
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Biomerica Announces Closing of $8 Million
Material agreement · Regulation FD disclosure · EX-99.3 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods ® IBS Treatment for Patients with Irritable Bowel Syndrome
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to approximately $4.6 Million
Results of operations · Other events · EX-99.1 to Form 8-K